Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 23 ... of the trial was that it compared the relative effectiveness of the BMAC to a control injection of a placebo. Neither the trial subjects nor the investigators know which material was ... Marrow, Cardiology, Cardiovascular, Clinical Trial Research, Conventional Therapies, Drug Development, Hematology, Ischemia, Peripheral Artery Disease, Pharmaceuticals, Quality ... as an innovative treatment option for CLI, however; previously published studies did not use a rapid, point of care method for processing the cells therefore making widespread ...
2009 NOV 23 ... as planned, and the science and research team is on track to complete the successive injection cycles for all twenty-seven Stage IV breast cancer patients in early 2010. The first ... FDA, Immunology, Immunotherapy, Medical Device, Oncology, Treatment, U.S. Food and Drug Administration, Women's Health, Mentor Capital Inc. This article was ... is that Quantum's exclusive licenses or patents cover the identification and use of Oncofetal Antigen - Immature Laminin Receptor (OFA) to treat cancer, and the OFA ...
2009 NOV 23 ... Microbix Biosystems Inc. (MBX:TSX) announced that KINLYTIC (urokinase for injection) has been approved in Canada for marketing and export. Health Canada's issuance of a ... has been approved in Canada for marketing and export. Health Canada's issuance of a Drug Identification Number for KINLYTIC gives Microbix the opportunity to market the product ... for nearly three years and generate revenue of about $30 million. Microbix plans to use this revenue to scale up KINLYTIC manufacturing at its Skyway production facility in ...
2009 NOV 23 ... and growing. MedImmune's monoclonal antibody, Synagis®, an intramuscular injection approved only for prophylactic use against RSV in premature infants, has annual ... products that address large market opportunities and are enabled by our game-changing drug delivery technologies. The acquisition of ViroPharma's portfolio is a perfect fit with ...
2009 NOV 23 ... ratio [OR] = 15.04; 95% confidence interval [CI] = 1.92, 117.53; P = .01), history of injection drug use (IDU; OR = 2.69; 95% CI = 1.19, 6.12; P = .02), and history of an STI (OR = 2.47; 95% CI ...
2009 NOV 23 ... in anti-Thy1 nephritis rats. In male F344 rats, anti-Thy1 nephritis was induced by the injection of an anti-Thy1 antibody. From three days before induction, nicorandil (10, 30 mg/kg per ... scientists in Shizuoka, Japan report. "Nicorandil, a therapeutic drug for angina and acute heart failure, have been reported to show antiproliferative ...
2009 NOV 24 ... cocaine use (adjusted odds ratio 1.6; 95% confidence interval [CI] 1.0 to 2.6) and injectiondrug history (adjusted odds ratio=0.5; 95% CI 0.3 to 0.9) were associated with the last ...
2009 NOV 23 ... drug-induced cytotoxicity. Rats were treated with 3 or 6 mg/kg cis-Platin (i.p., single injection) and urine samples were collected before and after drug or saline treatment," ... of biomarkers for drug-induced cytotoxicity may serve as a proof-of-principle for the use of urinary proteomics in assessment of drug-induced nephrotoxicity." ...
2009 NOV 23 ... 1) a prevention protocol, to receive simvastatin 20 mg.kg(-1).day(-1) by intraperitoneal injection or sildenafil 75 mg.kg(-1).day(-1) orally or the combination (or vehicle) for 2 weeks ... in right ventricular hypertrophy and pulmonary vascular muscularisation than either drug alone. Moreover, the combination augmented significantly endothelial nitric oxide ...
2009 NOV 24 ... primary cultures of rat cortical neurons. Memory loss induced by intracerebroventricular injection of ICR mice with 15 nmol A beta(25-35) was inhibited by chronic treatment with A. ... Sciences, Chungnam National University. This article was prepared by Drug Law Weekly editors from staff and other reports. Copyright 2009, Drug Law Weekly via ...
2009 NOV 24 ... these wormlike micelles remain in the circulation for at least a day after intravenous injection." "NIRF imaging further suggests that filomicelles convect into a tumor ... can penetrate into the tumor stroma. To assess a functional effect, the hydrophobic drug paclitaxel (tax) was loaded into both filomicelles and sonication-generated spherical ...
2009 NOV 23 ... facial noxious inputs and the effects of SB-705498 administered by intravenous (i.v.) injection," scientists in Sydney, Australia report. "Electrical and mechanical ... occurred by 1 h and reached 41% for dura and 24% for skin. Intravenous injection of drug vehicle did not produce significant suppression of responses to stimulation of either ...
2009 NOV 23 ... and 2006, all patients with carboplatin reinduction chemotherapy received an intradermal injection of 0.2 mu L of carboplatin and saline as negative control before chemotherapy. ... USA. Keywords: City:Wiesbaden, Country:Germany, Carboplatin, Chemotherapy, Drug Therapy, Drugs, Gynecology, Hypersensitivity, Oncology, Ovarian Cancer, Ovarian ... as a standard option in the so-called platinum-sensitive ovarian cancer, but its use can be limited by the occurrence of sometimes severe hypersensitivity reactions (HSRs). ...
2009 NOV 23 ... for visualization of extravasation and drug retention for the initial one hour after iv injection. Noninvasive imaging followed, providing evidence of drug accumulation in the tumor ...
2009 NOV 23 ... an active metabolite of AS, the bioavailability of 97.8% after intramuscular injection was fulfilled to a bioequivalence of that in intravenous treatment," wrote Q. Li and ... from the United States, "Artesunate (AS), a rapid, effective, and safe antimalarial drug, has been used for the treatment of malaria for decades. However, severe embryolethality ...
2009 NOV 23 ... in ovaries, kidney, liver, pancreas, mesenteric ganglion, blood, and muscle of the injection site by a qualitative polymerase chain reaction. The toxicology evaluation included ... Keywords: City:Havana, Country:Cuba, Biotechnology, DNA Research, DNA Vaccines, Drug Development, Gastroenterology, HCV, Hepatitis C Virus, Hepatology, Immunization, ...
2009 NOV 23 ... in the acute care environment. In the U.S., Cubist markets CUBICIN® (daptomycin for injection), the first antibiotic in a new class of anti-infectives called lipopeptides. In July ... needs, one in CDAD (Clostridium difficile-associated diarrhea) and the other in multi-drug resistant (MDR) Gram-negative infections. In addition, the Company, in collaboration ...
2009 NOV 23 ... the packaging of all botulinum toxin products, warning that toxins can spread from the injection site to other areas of the body, causing symptoms similar to those of botulism. ... as a result of the botulism poisoning. On April 30, 2009, the U.S. Food and Drug Administration issued a news release announcing that a boxed warning would be required ...
2009 NOV 23 ... safety in a species more closely related to humans. Non-human primates that received the injection of the follistatin transgene experienced pronounced and durable increases in muscle size ... muscle mass." The research team has developed a plan with the Food and Drug Administration and is currently in the process of performing the formal toxicology and ... studies to support initiating a human clinical trial. The potential use of this strategy for muscle strengthening has important implications for patients with ...
2009 NOV 23 ... and safety of the Company's lead oncology therapeutic Onrigin™ (laromustine) Injection prior to receiving regulatory approval from the FDA. Vion currently does not have the ... In the quarter, the Oncologic Drugs Advisory Committee (ODAC), which is the cancer drug advisory panel of the U.S. Food and Drug Administration (FDA), voted in favor of ...
